Table IV.
Formulation Composition of Amorphous and Crystalline Dosage Forms of Compound X for Dog Study
| ASD capsule formulation 3fa (API:PVP VA64) % | ASD capsule formulation 7aa (API:PVP K12) % | Crystalline tablet formulation without SDS % | Crystalline tablet formulation with SDS % | ||
|---|---|---|---|---|---|
| Intra-granular | Compound X | 20 | 20 | 20 | 20 |
| PVP VA64 | 40 | – | 20 | 20 | |
| PVP K12 | – | 60 | – | – | |
| Lactose | – | – | 20 | 13 | |
| MCC PH 101 | – | – | 15 | 10 | |
| SDS | – | – | – | 10 | |
| Crospovidone | – | – | 5 | 7 | |
| Extra-granular | SDS | 10 | – | – | – |
| MCC PH 102 | 18 | 8 | 15 | 15 | |
| CSD | 1 | 1 | 1 | 1 | |
| Magnesium stearate | 1 | 1 | 1 | 1 | |
| Crospovidone | 10 | 10 | 3 | 3 |
SDS sodium dodecyl sulphate, MCC microcrysalline cellulose, CSD colloidal silicon dioxide
aAmorphous solid dispersion blend filled in hard gelatin capsule